|
Tuesday, 17 Jan 2012
Minimally invasive cryoablation extends lives of women with ovarian cancer and is cost-effective, according to a study presented at the 4th annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET) in Miami, USA. [read more]
|
|
|
|
|
|
Tuesday, 29 Nov 2011
Bevacizumab used for metastatic breast cancer has not been shown to provide a benefit, in terms of delay in the growth of tumours that would justify its serious and potentially life-threatening risks. Nor is there evidence that use of bevacizumab will either help women with breast cancer live longer or improve their quality of life. [read more]
|
|
|
|
|
|
Friday, 04 Nov 2011
Advances in Yttrium-90 (Y-90) radioembolization for liver cancer, a leading cause of cancer deaths worldwide, are reported in studies in the October Journal of Vascular and Interventional Radiology (JVIR). [read more]
|
|
|
|
|
|
Wednesday, 02 Nov 2011
The Evolution Duodenal Controlled-Release stent (Cook Medical) offers a minimally invasive alternative to relieve the symptoms and potentially life-threatening complications resulting from duodenal obstruction, such as abdominal pain, vomiting, malnutrition and aspiration. [read more]
|
|
|
|
|
|
Wednesday, 12 Oct 2011
Presentations during the session “Microwave: effective ablation, supporting surgery” focused on both the technical and histopathological aspects of microwave ablation. [read more]
|
|
|
|
|
|
Thursday, 06 Oct 2011
TheraSphere (Nordion) is a yttrium-90 (Y-90) glass microsphere therapy for transarterial radioembolisation. [read more]
|
|
|
|
|
|
Tuesday, 04 Oct 2011
The purpose of the trial is to evaluate the safety and efficacy of the NanoKnife system for the treatment of early-stage hepatocellular carcinoma. NanoKnife is currently FDA cleared for surgical ablation of soft tissue. [read more]
|
|
|
|
|
|
Monday, 03 Oct 2011
With respect to the study’s primary endpoint of hepatic progression free survival (“hPFS”), the updated investigator-assessed results showed that patients in the chemosaturation arm demonstrated median hPFS of 8.0 months compared to 1.6 months in the best alternative care arm. [read more]
|
|
|
|
|
|
Thursday, 29 Sep 2011
Shinichi Hori, Rinku, Japan presented a new therapy for metastatic breast cancer using transarterial chemoembolization (TACE) for targeted drug delivery at the Emerging Therapies symposium at CIRSE in Munich, Germany. [read more]
|
|
|
|
|
|
Thursday, 22 Sep 2011
David Breen gives Interventional News his views on ablative technologies currently on the rise in interventional oncology. He says, “We are looking to move beyond the limitations of radiofrequency ablation, both in the volumes it can achieve and its oncologic efficacy. I think that the two standout modalities at the moment are microwave and cryoablation…” [read more]
|
|
|
|
|
